NEW YORK, March 14, 2017 /PRNewswire/ --
On Monday, benchmark US indices were in mixed colors as the NASDAQ Compositeclosed the trading session up 0.24%; the Dow Jones Industrial Average edged 0.10% lower; and the S&P 500 was up 0.04%. US markets made broad based gains with eight out of nine sectors finishing the day in green. Pre-market today, Stock-Callers.com
On Monday, shares in New York headquartered Delcath Systems Inc. recorded a trading volume of 5.39 million shares. The stock ended the day 1.67% lower at $0.12. The Company is trading below its 50-day and 200-day moving averages by 64.84% and 99.19%, respectively. Furthermore, shares of Delcath Systems, which operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver, have a Relative Strength Index (RSI) of 33.29. Free research report on DCTH is available at:
Cranbury, New Jersey-based Palatin Technologies Inc.'s stock finished Monday's session 0.29% lower at $0.34 with a total volume of 1.17 million shares traded. The Company's shares are trading below its 50-day and 200-day moving averages by 20.21% and 34.42%, respectively. Shares of Palatin Technologies, which develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the US, have an RSI of 32.68. The complimentary research report on PTN can be downloaded at:
Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc.'s stock edged 0.22% lower, to close the day at $23.15. The stock recorded a trading volume of 434,347 shares. AMAG Pharma's shares are trading 7.43% and 11.19% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which manufactures, develops, and commercializes therapeutics for women's health, anemia management, and cancer supportive care in the US, have an RSI of 48.06. Visit us today and access our complete research report on AMAG at:
On Monday, shares in Westbrook, Maine headquartered IDEXX Laboratories Inc. ended the session 0.88% higher at $151.60 with a total volume of 500,887 shares traded. IDEXX Laboratories' shares have gained 6.68% in the last one month and 27.62% in the previous three months. Furthermore, the stock has rallied 93.99% in the past one year. Shares of the Company, which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide, are trading at a PE ratio of 61.95. The stock is trading 14.73% above its 50-day moving average and 34.71% above its 200-day moving average. Moreover, the Company's shares have an RSI of 83.70. Get free access to your research report on IDXX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cardiopulmonary bypass is a technique which allows performing open heart surgical procedures in a ...
Acyclovir is an effective antiviral medication used primarily for treating the symptoms of herpes ...
Fasciotomy is a surgical procedure where the fascia is incised to relieve the compartmental ...View All